B van Hille

655 total citations
24 papers, 547 citations indexed

About

B van Hille is a scholar working on Molecular Biology, Oncology and Animal Science and Zoology. According to data from OpenAlex, B van Hille has authored 24 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Oncology and 3 papers in Animal Science and Zoology. Recurrent topics in B van Hille's work include Cancer therapeutics and mechanisms (9 papers), Lung Cancer Research Studies (5 papers) and DNA Repair Mechanisms (4 papers). B van Hille is often cited by papers focused on Cancer therapeutics and mechanisms (9 papers), Lung Cancer Research Studies (5 papers) and DNA Repair Mechanisms (4 papers). B van Hille collaborates with scholars based in France, Switzerland and Germany. B van Hille's co-authors include Bridget T. Hill, Dominique Perrin, Anna Kruczynski, Jean‐Marc Barret, Chantal Etiévant, Graeme Bilbe, Jean Rommelaere, Andreas Lohri, Nathalie Spruyt and Johnny Cornelis and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Journal of Virology.

In The Last Decade

B van Hille

23 papers receiving 536 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B van Hille France	14	404	128	98	71	66	24	547
Mariana Bucur Germany	14	224 0.6×	191 1.5×	130 1.3×	33 0.5×	17 0.3×	21	592
Hyeon Ung Park United States	10	381 0.9×	117 0.9×	42 0.4×	39 0.5×	14 0.2×	10	722
Amélie Weiss France	11	408 1.0×	88 0.7×	59 0.6×	34 0.5×	23 0.3×	18	678
Keya Bandyopadhyay United States	12	264 0.7×	122 1.0×	20 0.2×	18 0.3×	15 0.2×	17	492
Silvia Diviacco Italy	12	654 1.6×	47 0.4×	112 1.1×	43 0.6×	19 0.3×	13	823
R. Guy Smith United States	9	166 0.4×	107 0.8×	107 1.1×	16 0.2×	28 0.4×	9	372
Ivailo S. Mihaylov United States	9	518 1.3×	155 1.2×	85 0.9×	56 0.8×	6 0.1×	9	647
Ilaria Sciamanna Italy	21	944 2.3×	81 0.6×	256 2.6×	54 0.8×	15 0.2×	30	1.2k
Stefanie A.H. de Poot Netherlands	12	534 1.3×	133 1.0×	85 0.9×	83 1.2×	17 0.3×	12	733

Countries citing papers authored by B van Hille

Since Specialization

Citations

This map shows the geographic impact of B van Hille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B van Hille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B van Hille more than expected).

Fields of papers citing papers by B van Hille

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B van Hille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B van Hille. The network helps show where B van Hille may publish in the future.

Co-authorship network of co-authors of B van Hille

This figure shows the co-authorship network connecting the top 25 collaborators of B van Hille. A scholar is included among the top collaborators of B van Hille based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B van Hille. B van Hille is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mortier, Laurent, Astrid Blom, B van Hille, et al.. (2024). Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database. European Journal of Cancer. 209. 114261–114261. 1 indexed citations

Mortier, Laurent, Nicolás Meyer, M. Samimi, et al.. (2023). Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.. Journal of Clinical Oncology. 41(16_suppl). 9537–9537. 1 indexed citations

Lortet‐Tieulent, Joannie, et al.. (2021). Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database. Expert Review of Pharmacoeconomics & Outcomes Research. 21(5). 1135–1144. 3 indexed citations

Heinzlef, Olivier, et al.. (2020). Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France. PharmacoEconomics - Open. 4(4). 593–603. 5 indexed citations

Kastl, S., et al.. (2004). Simplification of rat intubation on inclined metal plate. AJP Advances in Physiology Education. 28(1). 29–32. 24 indexed citations

Kruczynski, Anna, Jean‐Marc Barret, B van Hille, et al.. (2004). Decreased Nucleotide Excision Repair Activity and Alterations of Topoisomerase IIα Are Associated with thein VivoResistance of a P388 Leukemia Subline to F11782, a Novel Catalytic Inhibitor of Topoisomerases I and II. Clinical Cancer Research. 10(9). 3156–3168. 12 indexed citations

Etiévant, Chantal, Anna Kruczynski, Jean‐Marc Barret, et al.. (2000). F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemotherapy and Pharmacology. 46(2). 101–113. 24 indexed citations

Hille, B van, Chantal Etiévant, Jean‐Marc Barret, Anna Kruczynski, & Bridget T. Hill. (2000). Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action. Anti-Cancer Drugs. 11(10). 829–841. 17 indexed citations

Perrin, Dominique, B van Hille, Jean‐Marc Barret, et al.. (2000). F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochemical Pharmacology. 59(7). 807–819. 77 indexed citations

10.

Perrin, Dominique, et al.. (2000). Expression in Yeast and Purification of Functional Recombinant Human Poly(ADP-RIBOSE)Polymerase(PARP). Comparative Pharmacological Profile with that of the Rat Enzyme. Journal of enzyme inhibition. 15(5). 461–469. 6 indexed citations

11.

Hille, B van, Dominique Perrin, & Bridget T. Hill. (1999). Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIα and IIβ isoforms. Anti-Cancer Drugs. 10(6). 551–560. 5 indexed citations

12.

Hille, B van, et al.. (1999). Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. British Journal of Cancer. 81(5). 800–807. 13 indexed citations

13.

Perrin, Dominique, B van Hille, & Bridget T. Hill. (1998). Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents. Biochemical Pharmacology. 56(4). 503–507. 25 indexed citations

14.

Lohri, Andreas, et al.. (1997). mRNA Expression, Measured by Quantitative Reverse Transcriptase Polymerase Chain Reaction, of Five Putative Drug Resistance Parameters, in Normal and Leukaemic Peripheral Blood and Bone Marrow. Acta Haematologica. 98(1). 1–7. 8 indexed citations

15.

Rochlitz, Christoph, Andreas Lohri, B van Hille, et al.. (1997). MTS1 expression and prognosis in acute myeloid leukemia. Annals of Hematology. 75(4). 141–144.

16.

Hille, B van, et al.. (1997). Assessment of drug-induced dysregulations among seven resistance-associated genes in human tumour cell lines.. PubMed. 16(6B). 3531–6. 12 indexed citations

17.

Lohri, Andreas, B van Hille, M. Bacchi, et al.. (1997). Five putative drug resistance parameters (MDR1/P‐glycoprotein, MDR‐associated protein, glutathione‐S‐transferase, bcl‐2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias. European Journal Of Haematology. 59(4). 206–215. 27 indexed citations

18.

Hille, B van, et al.. (1993). Identification of two subunit A isoforms of the vacuolar H(+)-ATPase in human osteoclastoma.. Journal of Biological Chemistry. 268(10). 7075–7080. 51 indexed citations

19.

Marer, Nadia Le, Vincent Laudet, E. C. Svensson, et al.. (1992). The c-Ha-ras oncogene induces increased expression of β-galactoside α-2,6-sialyltransferase in rat fibroblast (FR3T3) cells. Glycobiology. 2(1). 49–56. 72 indexed citations

20.

Hille, B van, Nathalie Salomé, Nathalie Spruyt, et al.. (1989). Limitations to the expression of parvoviral nonstructural proteins may determine the extent of sensitization of EJ-ras-transformed rat cells to minute virus of mice. Virology. 171(1). 89–97. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact